HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shepherd, F. A. Articles by Baker, M. A. Search for Related Content PubMed PubMed Citation Articles by Shepherd, F. A. Articles by Baker, M. A.

The Journal of Thoracic and Cardiovascular Surgery, Vol 86, 498-506, Copyright © 1983 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer

FA Shepherd, RJ Ginsberg, WK Evans, R Feld, JD Cooper, R Ilves, TR Todd, FG Pearson, PF Waters and MA Baker

To assess the role of operation in the treatment and prevention of local recurrence in limited small cell lung cancer, we analyzed retrospectively 35 patients undergoing surgical resection for small cell lung cancer between 1976 and 1982. Twenty-eight patients underwent resection for presumed non-small cell histology. Seven later patients had planned combined modality therapy consisting of chemotherapy and prophylactic cranial irradiation followed by surgical resection and irradiation to the primary site. Twenty-four patients received adjuvant postoperative chemotherapy and/or radiotherapy. All patients have been treated and followed up for a minimum of 1 year. There were 19 patients in Stage I and 16 in Stages II and III. In 15 patients, relapse has occurred. The commonest site of first relapse was brain (7/15). Five of these patients had received prophylactic cranial irradiation. In only two patients was there a relapse locally in the hemithorax and/or mediastinum--one with NO disease and one with N1 disease. No local recurrence was noted in six patients with N2 disease. Only two relapses have occurred beyond 1 year--both in brain. In those patients surviving more than 2 years, no relapses have occurred. The median survival time for patients with Stage I disease is 158 weeks and for those with Stages II and III, 92.4 weeks. The median survival time for the whole group is 92.4 weeks with a projected 5 year survival rate of 24%. It appears that surgical resection may help to prevent local recurrence in small cell lung cancer, even in N1 and N2 disease. In our series, projected 5 year survival rates are similar to those seen in the surgical treatment of patients with non-small cell lung cancer. The eventual role of operation in the prevention of local recurrence and improvement in overall survival of limited small cell lung cancer awaits prospective randomized trials.

This article has been cited by other articles:

				V. Chandra, M. S. Allen, F. C. Nichols III, C. Deschamps, S. D. Cassivi, and P. C. Pairolero The Role of Pulmonary Resection in Small Cell Lung Cancer Mayo Clin. Proc., May 1, 2006; 81(5): 619 - 624. [Abstract] [Full Text] [PDF]

				R. Tsuchiya, K. Suzuki, Y. Ichinose, Y. Watanabe, T. Yasumitsu, N. Ishizuka, and H. Kato Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101) J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 977 - 983. [Abstract] [Full Text] [PDF]

				A. Badzio, K. Kurowski, H. Karnicka-Mlodkowska, and J. Jassem A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 183 - 188. [Abstract] [Full Text] [PDF]

				British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britai, and Ireland Working Party Guidelines on the selection of patients with lung cancer for surgery Thorax, February 1, 2001; 56(2): 89 - 108. [Full Text]